MNG411
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- P53_PATHWAY+0.325
- MYC_TARGETS_V2+0.311
- WNT_BETA_CATENIN_SIGNALING+0.296
- PEROXISOME+0.275
- FATTY_ACID_METABOLISM+0.257
- DNA_REPAIR+0.250
- XENOBIOTIC_METABOLISM+0.227
- NOTCH_SIGNALING+0.212
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.195
- HEME_METABOLISM+0.190
Top 10 suppressed
- KRAS_SIGNALING_UP-0.326
- G2M_CHECKPOINT-0.320
- E2F_TARGETS-0.311
- PROTEIN_SECRETION-0.289
- ALLOGRAFT_REJECTION-0.280
- PANCREAS_BETA_CELLS-0.280
- MTORC1_SIGNALING-0.258
- ANDROGEN_RESPONSE-0.230
- INFLAMMATORY_RESPONSE-0.227
- SPERMATOGENESIS-0.227
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG571 | — | — | 0.756 |
| 2 | MNG545 | — | — | 0.690 |
| 3 | SRR23303772 | — | — | 0.682 |
| 4 | SRR12475127 | — | — | 0.659 |
| 5 | DRR168554 | — | — | 0.646 |
| 6 | SRR12475123 | — | — | 0.639 |
| 7 | MNG321 | — | — | 0.637 |
| 8 | 1e82995c-f318-4225-96d4-f1e98bcbf60b | — | — | 0.623 |
| 9 | TCGA-E2-A14U-01A-11R-A22K-07 | — | A | 0.622 |
| 10 | DRR168596 | — | — | 0.620 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| P53_PATHWAY | 0.325 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.311 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.296 | Inavolisib | — uncovered |
| PEROXISOME | 0.275 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.257 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.227 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.212 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.195 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.180 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.177 | Inavolisib | — uncovered |
| MYOGENESIS | 0.144 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| APOPTOSIS | 0.133 | Idelalisib | — uncovered |
| COAGULATION | 0.108 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.107 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.093 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.075 | Inavolisib | — uncovered |